financetom
Business
financetom
/
Business
/
Lazard expects dealmaking to pick up, tariffs to be measured
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lazard expects dealmaking to pick up, tariffs to be measured
Dec 11, 2024 3:10 PM

NEW YORK (Reuters) - Investment bank Lazard's ( LAZ ) CEO, Peter Orszag, predicted a surge in dealmaking momentum to continue into next year, helped by private equity activity.

Wall Street executives have expressed optimism that the incoming Trump administration will usher in deregulation and more openness to mergers and acquisitions. The bullish views come as investment banking activity recovers from a two-year dry spell.

"There were a lot of large transactions that were being informally discussed that now are more in 'let's see if we can really make this happen,' and that's pretty much across the board," Orszag said in an interview on Wednesday at the Reuters NEXT conference in New York.

President-elect Donald Trump, who takes office on Jan. 20, has said he will slap 25% tariffs on imports from Mexico and Canada, as well as additional duties on Chinese goods, which would hit companies in sectors from autos to retail and has sparked concern among investors.

"There may have been a lot of rhetoric, but when you get to governing and want to make sure that inflation doesn't begin to spike, things will be done in a more tempered manner," Orszag said.

He was also bullish about Lazard's ( LAZ ) prospects for next year.

New York-based Lazard's ( LAZ ) financial advisory revenue climbed 39% in the third quarter to $371 million, driving a 50% jump in revenue to $785 million.

Lazard ( LAZ ) was the ninth-most active investment bank in global M&A in the first nine months of the year, ranked by fees, according to data from Dealogic.

To view the live broadcast of the World Stage go to the Reuters NEXT news page: https://www.reuters.com/world/reuters-next/

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSK Names Luke Miels CEO Designate
GSK Names Luke Miels CEO Designate
Sep 29, 2025
04:49 AM EDT, 09/29/2025 (MT Newswires) -- GSK (GSK) said Monday it has appointed Luke Miels chief executive officer designate. Miels, who most recently served as the company's chief commercial officer, will assume the role and join the board on Jan. 1, succeeding Emma Walmsley. Walmsley is stepping down from GSK and is planning to pursue new ventures. Shares of...
AstraZeneca Plans Direct Listing of Shares on NYSE
AstraZeneca Plans Direct Listing of Shares on NYSE
Sep 29, 2025
04:48 AM EDT, 09/29/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday it plans a direct listing of its shares on the New York Stock Exchange, replacing the existing US listing of its American depositary receipts on Nasdaq. The company's board recommended to its shareholders a harmonized listing structure for its shares across the London Stock Exchange, Nasdaq Stockholm...
Chip lab imec names new CEO in AI-focused transition
Chip lab imec names new CEO in AI-focused transition
Sep 29, 2025
Sept 29 (Reuters) - Belgian chip research hub imec will appoint Patrick Vandenameele as its new chief executive with current CEO Luc Van den hove becoming chairman, the company told Reuters on Monday. Belgium's imec, one of the world's top semiconductor R&D firms, has made the change to help it adapt to the changing demands of artificial intelligence (AI) chipmaking,...
Biogen, Eisai Say China Approves Maintenance Dosing Regimen for Alzheimer's Drug
Biogen, Eisai Say China Approves Maintenance Dosing Regimen for Alzheimer's Drug
Sep 29, 2025
04:53 AM EDT, 09/29/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Sunday their Alzheimer's therapy Leqembi has been approved for once every four weeks intravenous maintenance dosing by the National Medical Products Administration in China. Leqembi was earlier approved for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease in China,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved